Last reviewed · How we verify

Cefepime Injection — Competitive Intelligence Brief

Cefepime Injection (Cefepime Injection) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fourth-generation cephalosporin. Area: Infectious Disease.

marketed Fourth-generation cephalosporin Penicillin-binding proteins (PBPs) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Cefepime Injection (Cefepime Injection) — Murdoch Childrens Research Institute. Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cefepime Injection TARGET Cefepime Injection Murdoch Childrens Research Institute marketed Fourth-generation cephalosporin Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fourth-generation cephalosporin class)

  1. Murdoch Childrens Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cefepime Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/cefepime-injection. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: